RSS Feed

News


Cellmid Limited (ASX: CDY) is pleased to advise that a manuscript describing the screening approach and clinical study carried out by Cellmid’s wholly owned subsidiary, Advangen Limited, has been published in the journal Clinical, Cosmetic, and Investigational Dermatology 10: 71-85. 27 Feb 2017.
Cellmid Limited (ASX: CDY) is pleased to advise that the European Patent Office has issued Notice of Allowance for the patent application number 11746751.4 entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” (midkine or MK alopecia patent).
Cellmid Limited (ASX: CDY) is pleased to advise that the US Patent and Trademark Office has issued Notice of Allowance for the patent application number 14/464,358 entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” (midkine or MK alopecia patent).
Cellmid Limited (ASX: CDY) provides this update to shareholders on recent developments regarding its midkine diagnostic license to Pacific Edge Biotechnology Limited (Pacific Edge).
"Hair growth equals Sales Growth equals Share Price Growth" Lodge Partners Analyst Marc Sinatra reports on Cellmid Limited